Latest Stories from Medicaldlvr.it Promoted Storieshttps://static.dlvr.it/images/d.pnghttps://static.dlvr.it/images/favicon.icotag:news.dlvr.it,2015-03-21:/category/medical2015-03-21T21:13:52-07:00tag:news.dlvr.it,2015-03-21:3706662015-03-21T15:00:08-07:00NBA All-Star Chris Paul joins Kaiser Permanente in welcoming two Special Olympics basketball teams to a private basketball clinic at the Crenshaw Family YMCA in Los Angeles.]]>tag:news.dlvr.it,2015-03-21:3671552015-03-21T07:00:02-07:00
Samsung to demonstrate ultrasound technology in stroke detection on
nationwide cycling tour, led by former Intel executive Sean Maloney, to
generate awareness about preventing stroke
]]>tag:news.dlvr.it,2015-03-21:3733232015-03-21T02:46:08-07:00]]>tag:news.dlvr.it,2015-03-20:3672592015-03-20T19:01:10-07:00]]>tag:news.dlvr.it,2015-03-20:3593122015-03-20T14:30:01-07:00]]>tag:news.dlvr.it,2015-03-20:3625122015-03-20T13:41:08-07:00
Paul Friedman to continue to serve as Executive Chairman and Bill
Rastetter to continue to serve as Lead Independent Director
]]>tag:news.dlvr.it,2015-03-20:3651392015-03-20T12:11:08-07:00
- Initiative based on data that targeted delivery technology crosses
blood brain barrier -
]]>tag:news.dlvr.it,2015-03-20:3729372015-03-20T12:06:09-07:00HealthTrust invites suppliers to submit new healthcare-related technology products for possible inclusion in its first Innovation Summit. Deadline is March 31.]]>tag:news.dlvr.it,2015-03-20:3693122015-03-20T11:43:09-07:00]]>tag:news.dlvr.it,2015-03-20:3721592015-03-20T11:00:11-07:00
Company Opens Optical Service Center to Service the Eye-care
Providers in New York City
]]>tag:news.dlvr.it,2015-03-20:3666482015-03-20T10:47:02-07:00]]>tag:news.dlvr.it,2015-03-20:3680652015-03-20T10:45:08-07:00
Prescription Drug Abuse Medical Task Force Announces Los Angeles
County-wide Plan
]]>tag:news.dlvr.it,2015-03-20:3618432015-03-20T10:01:15-07:00
Nearly double the percentage of patients on BI 655066 with clear or
almost clear skin (PASI 90) after 12 weeks vs. ustekinumab1
BI 655066 selectively blocks IL-23, a key protein involved in
psoriatic skin inflammation1
]]>tag:news.dlvr.it,2015-03-20:3647402015-03-20T10:01:08-07:00
Nearly double the percentage of patients on BI 655066* with
clear or almost clear skin (PASI 90) after 12 weeks vs. ustekinumab
BI 655066 selectively blocks IL-23, a key protein involved in
psoriatic skin inflammation
]]>tag:news.dlvr.it,2015-03-20:3729062015-03-20T10:00:24-07:00
Improvements in the severity of preexisting nail, scalp and
palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA
responders through week 52 in ESTEEM 2
OTEZLA improved the severity of palmoplantar psoriasis at week 16 in
a subset of patients across three trials
Long-term safety profile for up to 104 weeks in ESTEEM 1 was
consistent with previously reported data from OTEZLA clinical trial
programs, with no new safety signals and no clinically meaningful
changes in laboratory values
]]>
NBA All-Star Chris Paul joins Kaiser Permanente in welcoming two Special Olympics basketball teams to a private basketball clinic at the Crenshaw Family YMCA in Los Angeles.]]>
Samsung to demonstrate ultrasound technology in stroke detection on
nationwide cycling tour, led by former Intel executive Sean Maloney, to
generate awareness about preventing stroke
]]>
]]>
]]>
Paul Friedman to continue to serve as Executive Chairman and Bill
Rastetter to continue to serve as Lead Independent Director
]]>
- Initiative based on data that targeted delivery technology crosses
blood brain barrier -
]]>
HealthTrust invites suppliers to submit new healthcare-related technology products for possible inclusion in its first Innovation Summit. Deadline is March 31.]]>
Company Opens Optical Service Center to Service the Eye-care
Providers in New York City
]]>
Prescription Drug Abuse Medical Task Force Announces Los Angeles
County-wide Plan
]]>
Nearly double the percentage of patients on BI 655066 with clear or
almost clear skin (PASI 90) after 12 weeks vs. ustekinumab1
BI 655066 selectively blocks IL-23, a key protein involved in
psoriatic skin inflammation1
]]>
Nearly double the percentage of patients on BI 655066* with
clear or almost clear skin (PASI 90) after 12 weeks vs. ustekinumab
BI 655066 selectively blocks IL-23, a key protein involved in
psoriatic skin inflammation
]]>
Improvements in the severity of preexisting nail, scalp and
palmoplantar psoriasis achieved at week 16 were maintained in OTEZLA
responders through week 52 in ESTEEM 2
OTEZLA improved the severity of palmoplantar psoriasis at week 16 in
a subset of patients across three trials
Long-term safety profile for up to 104 weeks in ESTEEM 1 was
consistent with previously reported data from OTEZLA clinical trial
programs, with no new safety signals and no clinically meaningful
changes in laboratory values
]]>